株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

破傷風 : パイプライン製品の分析

Tetanus - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192846
出版日 ページ情報 英文 100 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
破傷風 : パイプライン製品の分析 Tetanus - Pipeline Review, H2 2016
出版日: 2016年09月21日 ページ情報: 英文 100 Pages
概要

破傷風とは、破傷風菌により引き起こされる重い疾患です。主な徴候・症状として、あごの筋肉のけいれんや硬直化、嚥下障害、腹筋の硬直化、発熱、発汗、血圧・心拍数の上昇などがあります。疾病素質には火傷や、外科手術による外傷、耳の感染症、外傷部分近辺の浮腫、足部潰瘍(からの感染)などが含まれています。主な治療薬には抗生物質や鎮静剤、β遮断薬などがあります。

当レポートでは、世界各国での破傷風治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

破傷風の概要

治療薬の開発

  • 破傷風向けパイプライン製品:概要
  • 破傷風向けパイプライン製品:比較分析

各企業で開発中の破傷風治療薬

大学/研究機関で研究中の破傷風治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

破傷風治療薬:開発中の製品の一覧(企業別)

破傷風治療薬:研究中の製品の一覧(大学/研究機関別)

破傷風治療薬の開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Bharat Biotech International Limited
  • BioClonetics Immunotherapeutics, Inc.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Indian Immunologicals Limited
  • 化学及血清療法研究所(化血研)
  • LG Life Science LTD.
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

破傷風:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

破傷風治療薬:開発が休止状態の製品

破傷風治療薬:開発が中止された製品

破傷風関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8482IDB

Summary

Global Markets Direct's, 'Tetanus - Pipeline Review, H2 2016', provides an overview of the Tetanus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tetanus
  • The report reviews pipeline therapeutics for Tetanus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tetanus therapeutics and enlists all their major and minor projects
  • The report assesses Tetanus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tetanus

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tetanus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tetanus Overview
  • Therapeutics Development
    • Pipeline Products for Tetanus - Overview
    • Pipeline Products for Tetanus - Comparative Analysis
  • Tetanus - Therapeutics under Development by Companies
  • Tetanus - Therapeutics under Investigation by Universities/Institutes
  • Tetanus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Tetanus - Products under Development by Companies
  • Tetanus - Products under Investigation by Universities/Institutes
  • Tetanus - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Bharat Biotech International Limited
    • BioClonetics Immunotherapeutics, Inc.
    • Biological E. Limited
    • Boryung Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline Plc
    • Green Cross Corporation
    • Indian Immunologicals Limited
    • Kaketsuken K.K.
    • LG Life Science LTD.
    • Panacea Biotec Limited
    • Prometheon Pharma, LLC
    • Sanofi Pasteur SA
    • Serum Institute of India Limited
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Tetanus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Eupenta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-1107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3111A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Tetanus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Tetanus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Target Tetanus Toxin for Tetanus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tetanus - Dormant Projects
  • Tetanus - Discontinued Products
  • Tetanus - Product Development Milestones
    • Featured News & Press Releases
      • Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta
      • Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
      • Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
      • Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age
      • Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
      • Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
      • Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets
      • Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency
      • Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
      • Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
      • Jun 13, 2005: U.S. FDA Licenses sanofi Pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
      • Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine
      • Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
      • Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.
      • May 14, 2002: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tetanus, H2 2016
  • Number of Products under Development for Tetanus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Tetanus - Pipeline by Bharat Biotech International Limited, H2 2016
  • Tetanus - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016
  • Tetanus - Pipeline by Biological E. Limited, H2 2016
  • Tetanus - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016
  • Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Tetanus - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Tetanus - Pipeline by Green Cross Corporation, H2 2016
  • Tetanus - Pipeline by Indian Immunologicals Limited, H2 2016
  • Tetanus - Pipeline by Kaketsuken K.K., H2 2016
  • Tetanus - Pipeline by LG Life Science LTD., H2 2016
  • Tetanus - Pipeline by Panacea Biotec Limited, H2 2016
  • Tetanus - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Tetanus - Pipeline by Sanofi Pasteur SA, H2 2016
  • Tetanus - Pipeline by Serum Institute of India Limited, H2 2016
  • Tetanus - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Tetanus - Dormant Projects, H2 2016
  • Tetanus - Dormant Projects (Contd..1), H2 2016
  • Tetanus - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Tetanus, H2 2016
  • Number of Products under Development for Tetanus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top